KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $15.9 million.

  • Bio-Rad Laboratories' Share-based Compensation fell 304.88% to $15.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.8 million, marking a year-over-year decrease of 202.81%. This contributed to the annual value of $58.0 million for FY2025, which is 690.21% down from last year.
  • Bio-Rad Laboratories' Share-based Compensation amounted to $15.9 million in Q4 2025, which was down 304.88% from $14.9 million recorded in Q3 2025.
  • Bio-Rad Laboratories' 5-year Share-based Compensation high stood at $18.1 million for Q4 2022, and its period low was $11.4 million during Q2 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $15.3 million (2021), whereas its average is $14.8 million.
  • Per our database at Business Quant, Bio-Rad Laboratories' Share-based Compensation surged by 2954.55% in 2021 and then crashed by 1049.72% in 2023.
  • Over the past 5 years, Bio-Rad Laboratories' Share-based Compensation (Quarter) stood at $15.0 million in 2021, then increased by 20.67% to $18.1 million in 2022, then decreased by 10.5% to $16.2 million in 2023, then rose by 1.23% to $16.4 million in 2024, then dropped by 3.05% to $15.9 million in 2025.
  • Its Share-based Compensation stands at $15.9 million for Q4 2025, versus $14.9 million for Q3 2025 and $16.4 million for Q4 2024.